
Beverly M K Biller MD
Diabetes, Lipid Metabolism, Pituitary Disorders & Neuroendocrinology
Professor of Medicine, Massachusetts General Hospital
Join to View Full Profile
0 Emerson PlSte 112Boston, MA 02114
Phone+1 617-726-7948
Fax+1 617-726-5027
Are you Dr. Biller?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Beverly Biller, MD is an endocrinologist in Boston, Massachusetts. She is currently licensed to practice medicine in Massachusetts. She is a Professor of Medicine at Massachusetts General Hospital.
Education & Training
- Mass General Brigham/Massachusetts General HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 1987 - 1989
- Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1987 - 1989
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1983 - 1986
- University of Oklahoma College of MedicineClass of 1983
Certifications & Licensure
- MA State Medical License 1989 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Publications & Presentations
PubMed
- Osilodrostat improves blood pressure and glycemic control in patients with Cushing's disease: a pooled analysis of LINC 3 and LINC 4 studies.Maria Fleseriu, Rosario Pivonello, John Newell-Price, Mônica R Gadelha, Beverly M K Biller
Pituitary. 2025-01-25 - 9 citationsAcromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine.Mônica R Gadelha, Alessandra Casagrande, Christian J Strasburger, Martin Bidlingmaier, Peter J Snyder
The Journal of Clinical Endocrinology and Metabolism. 2024-12-18 - 1 citationsOsilodrostat treatment in patients with Cushing's disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4).Akira Shimatsu, Beverly Mk Biller, Maria Fleseriu, Rosario Pivonello, Eun Jig Lee
Endocrine Journal. 2024-12-02